Regeneron Starts COVID-19 Antibody Cocktail Late-Stage Trial, Shares Rise
Monday, 6 July 2020 ()
Regeneron Pharmaceuticals Inc said on Monday it began late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating COVID-19, sending its shares up nearly 4%.The trial, run jointly with the National Institute of Allergy and... |
|
|||